Journal of Clinical Oncology
Articles in this Issue
A phase 2 clinical trial in progress of (Z)-endoxifen plus goserelin as neoadjuvant therapy in premenopausal women with ER+/HER2– breast cancer (EVANGELINE).
TPS655 Background: Early (14-28 day) on-treatment suppression of tumor proliferation during neoadjuvant endocrine therapy...
Optimal subsequent-line strategies for <i>EGFR</i> -mutant NSCLC after TKI progression: A systematic review and network meta-analysis.
e20506 Background: Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is ine...
Association of drug industry payments to oncologists and use of guideline-preferred cancer treatments.
11059 Background: Payments from the drug industry to oncologists are common and influence physicians’ prescribing decision...
The efficacy of concurrent chemoradiotherapy with/without nimotuzumab in high-risk patients with locally advanced head and neck squamous cell carcinoma after surgery: A real-world study.
e18002 Background: Patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) harboring high-risk pat...
Early-onset cancer signature (EOCS): Pan-cancer molecular alterations with prognostic significance in early-onset (EOC) and late-onset (LOC) cancer.
3126 Background: Early-onset cancer (EOC) is an emerging global epidemic with biological and molecular features distinct f...
Alignment of Vietnam’s national Essential Medicines List with cancer incidence and the WHO EML.
e23052 Background: Essential Medicines Lists (EMLs) are key policy instruments for ensuring equitable access to cancer tre...
Graft and infectious outcomes following immune checkpoint inhibitor exposure in kidney transplant recipients with non-melanoma skin cancer: A multicenter real-world study.
e21563 Background: Kidney transplant recipients (KTRs) face a disproportionately high risk of non-melanoma skin cancer (NM...
Risk prediction models for familial breast cancer: A Cochrane systematic review and meta-analysis.
10545 Background: Women with a family history of breast cancer (BC) have an increased risk of developing the disease. Seve...
GK01 stemness-enriched tumor-reactive T-cell therapy plus IL-2 in advanced solid tumors: ORR and clonal persistence results in a first-in-human phase I study (GUARDIAN-01).
2540 Background: T-cell exhaustion and poor persistence limit tumor infiltrated lymphocytes (TILs) efficacy in solid tumor...
Prostate-specific antigen outcomes of darolutamide and androgen deprivation therapy in patient subgroups by age, comorbidities, and concomitant medications: ARANOTE post hoc analyses.
5103 Background: Darolutamide (DARO) + androgen deprivation therapy (ADT) significantly improved radiological progression-...
A multi-institutional, single-arm, phase 2 study of durvalumab plus amrubicin in patients with relapsed extensive-stage small cell lung cancer (Aphrodite trial).
8105 Background: In patients (pts) with sensitive relapsed (SR) and refractory relapsed (RR) small cell lung cancer (SCLC)...
First-in-human phase 1 study of TQB6411, an EGFR/c-Met bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors.
3032 Background: EGFR and c-Met overexpression are common across various solid tumors. TQB6411 is a novel ADC binding to b...
Impact of lymph node dissection extent on disease-free survival with postoperative nivolumab plus concurrent chemoradiotherapy in head and neck squamous cell carcinoma: A post-hoc analysis of the NIVOPOSTOP trial.
6001 Background: Postoperative nivolumab added to concurrent Chemo-Radiotherapy (CRT) after surgery has been shown to impr...
Association of asynchronous, time-flexible digital multidisciplinary care with overall survival in advanced biliary tract cancer treated with immune checkpoint inhibitors.
4116 Background: Delayed recognition and fragmented management of immune-related adverse events (irAEs) can trigger unnece...
Immune-related adverse events with immune checkpoint inhibitors: Insights from real-world practice in Brazil.
e23338 Background: Immune checkpoint inhibitors (ICIs) are widely used in the treatment of multiple malignancies and are a...
Deciphering the intricate crosstalk of the EFNA1-EPHA3 axis in orchestrating the proangiogenic niche of cervical adenocarcinoma: A promising therapy target.
e17508 Background: Cervical adenocarcinoma (ADC) shows more malignant phenotypes and poorer prognosis compared to squamous...
Evaluation of fine-tuned small language models (SLMs) vs large language models (LLMs) in modeled patient conversations for lung cancer screening.
e24116 Background: Lung Cancer Screening (LCS) uptake in the US remains suboptimal at approximately 18%, with disproportio...
A retrospective analysis examining liquid biopsies with tissue biopsies in patients with advanced non–small cell lung cancer.
e20683 Background: Non-small cell lung cancer (NSCLC) is genetically diverse, often harboring actionable mutations (AM) th...
A double-blind, double-dummy, randomized, controlled phase 3 trial of iparomlimab and tuvonralimab (QL1706) vs QL1604 as consolidation therapy following concurrent or sequential chemoradiotherapy (cCRT/sCRT) in patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).
TPS8133 Background: LS-SCLC is a highly aggressive malignancy with poor prognosis. Positioning effective consolidation str...
Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible, newly diagnosed multiple myeloma patients: Phase 1/2 BelaDRd study.
7512 Background: The MAIA trial established daratumumab with lenalidomide, dexamethasone (DRd) as standard therapy for tra...
Validation of an integrated statistical framework for reconstructing individual-patient data from time-to-event curves.
e23432 Background: Published time-to-event results are most often presented as Kaplan-Meier (KM) plots, but the underlying...
Multimodal risk phenotyping of early-onset colorectal cancer.
10561 Background: Early-onset colorectal cancer (EOCRC) is rising rapidly, yet its risk profile is incompletely defined. P...
Does where you live matter?: State-level variation in liver cancer mortality.
e16344 Background: In the United States, liver cancer is among the most lethal cancers, highlighting the need for improved...
Common symptoms, quality of life, and lifestyle factors reported by cancer survivors attending the Sydney Cancer Survivorship Multidisciplinary Clinic.
12113 Background: Sydney Cancer Survivorship Clinic (SCSC) provides multidisciplinary care for cancer survivors. During an...
Evaluating CT-derived body composition and colorectal cancer risk: A group-based trajectory modeling morphomics study.
e22530 Background: Obesity is an known risk factor for colorectal cancer (CRC), yet body mass index (BMI) incompletely cap...